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Abstract
Cytomegaloviruses encode homologs of cellular immune effector proteins, including chemokines (CKs) and CK receptor-like G
protein-coupled receptors (GPCRs). Sequence of the guinea pig cytomegalovirus (GPCMV) genome identified an open reading frame (ORF)
which predicted a 101 amino acid (aa) protein with homology to the macrophage inflammatory protein (MIP) subfamily of CC () CKs,
designated GPCMV-MIP. To assess functionality of this CK, recombinant GPCMV-MIP was expressed in HEK293 cells and assayed for
its ability to bind to and functionally interact with a variety of GPCRs. Specific signaling was observed with the hCCR1 receptor, which
could be blocked with hMIP 1 in competition experiments. Migration assays revealed that GPCMV-MIP was able to induce chemotaxis
in hCCR1-L1.2 cells. Antisera raised against a GST–MIP fusion protein immunoprecipitated species of 12 and 10 kDa from GPCMV-
inoculated tissue culture lysates, and convalescent antiserum from GPCMV-infected animals was immunoreactive with GST-MIP by ELISA
assay. These results represent the first substantive in vitro characterization of a functional CC CK encoded by a cytomegalovirus.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Human cytomegalovirus (HCMV) is a pathogen respon-
sible for serious disease in immunocompromised patients,
including newborns (Schleiss, 2003). Infection with HCMV
is lifelong, and reactivation from latency may occur under
conditions of immunosuppression (transplantation, HIV in-
fection), producing disease. HCMV encodes genes that con-
fer immunomodulatory functions which may impact the
efficiency of infection, dissemination, reactivation, and per-
sistent infection in the host (Hengel et al., 1998; Gruhler and
Fruh, 2000; Vink et al., 2001; Saederup and Mocarski,
2002). Such “immune evasion” genes include homologs of
chemokines (CKs), chemokine receptor-like G protein-cou-
pled receptors (GPCRs), and modulators of antigen process-
ing and presentation (Hengel et al., 1998; Mocarski, 2002;
Alcami and Koszinowski, 2000). In addition to contributing
to modification of host immune responses, some of these
viral proteins may play a role in promoting dissemination
during acute infection. This is of particular relevance for the
CKs, which are small, secreted proteins that control leuko-
cyte migration and trafficking (Dairaghi et al., 1998;
Hughes and Yeager, 1999). Understanding the role these
genes play in viral pathogenesis could provide insights into
the optimal strategies for developing therapeutic interven-
tions, particularly for vaccines which could target the pre-
vention of the devastating sequelae of congenital HCMV
infection (Plotkin, 1999).
A variety of CKs have been described for both HCMV
and murine cytomegalovirus (MCMV). Interestingly, these
CKs share neither sequence conservation nor similar posi-
tioning within their respective genomes, and in fact, are
members of different CK subfamilies (Zlotnik and Yoshie,
2000). HCMV genes UL146 and UL147 code for proteins
with sequence characteristics of CXC chemokines, while
* Corresponding author. Departments of Pediatrics and Molecular and
Developmental Biology, Children’s Hospital Research Foundation, 3333
Burnet Avenue, Cincinnati, Ohio 45229. Fax: 1-513-636-7655.
E-mail address: schlm0@cchmc.org (M.R. Schleiss).
R
Available online at www.sciencedirect.com
Virology 316 (2003) 202–212 www.elsevier.com/locate/yviro
0042-6822/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0042-6822(03)00581-6
MCMV encodes a CC chemokine homolog, MCK-2 (Flem-
ing et al., 1999; Penfold et al., 1999; Saederup et al., 1999,
2001). The CXC chemokine encoded by HCMV, UL146, is
an active neutrophil chemoattractant, and is designated viral
CXC chemokine-1 (vCXC1). Receptor-ligand binding stud-
ies indicate that it is as potent as host IL-8, and functions via
the CXCR2 receptor. The MCMV MCK-2 consists of a CK
domain derived from ORF m131 (denoted MCK-1) and a
domain derived from ORF m129. Studies of the pathoge-
nicity of recombinant viruses deleted of the m131/129 locus
indicate that this CK confers increased inflammation, higher
levels of viremia, and higher viral titers in salivary glands,
consistent with a role in promoting dissemination, possibly
related to recruitment of mononuclear cells during acute
infection.
Although additional homologs of viral CKs are predicted
by sequence analysis of other CMVs (Vink et al., 2000;
Davison et al., 2003); there has to date been limited func-
tional assessment of these putative CKs. Assessment of the
functional activity of CMV CKs, as well as the in vivo
phenotype of mutant viruses deleted of these genes, could
provide important insights into the role these proteins play
in pathogenesis. Elucidation of the function of these CKs
could, in addition, enable development of novel therapeutic
and preventative strategies. Of particular interest is the elu-
cidation of the role CKs could play in the in utero patho-
genesis of CMV. Among the animal models of CMV infec-
tion, the guinea pig cytomegalovirus (GPCMV) model is
uniquely useful for addressing such questions, since, in
contrast to the CMVs of other small mammals, GPCMV,
similar to HCMV, crosses the placenta, causing fetal infec-
tion (Schleiss, 2002). Studies of GPCMV have been facil-
itated by the cloning of the viral genome as a bacte-
rial artificial chromosome (BAC) in Escherichia coli
(McGregor and Schleiss, 2003). Sequence analysis of
cloned subfragments of the genome has, interestingly, re-
vealed the presence of open reading frames (ORFs) not
present in other CMVs. One such ORF was found to map
near the leftward terminus of the GPCMV genome, within
the HindIII “D” fragment of the genome. Analysis of the
deduced amino acid (aa) sequence of this ORF suggested
that it encoded a CK, predicted to be of the CC () family,
in particular sharing strong identity with the hMIP -1 sub-
family (Haggerty and Schleiss, 2002). These studies were
therefore undertaken to further characterize this gene and to
examine the functionality of this putative CK homolog.
Results
The GPCMV genome encodes a homolog of the CC ()
CK gene family
Sequence analysis of the GPCMV genome identified a
homolog of the CC CK family, mapping to the HindIII “D”
region of the viral genome (Fig. 1A). This CK is positioned
in right-to-left orientation, relative to the genomic configu-
ration of GPCMV. The ORF is 101 aa in length and has
homology to the CC chemokine family, including the sig-
nature positioning of two adjacent N-terminal cysteine res-
idues (Fig. 1B). The ORF is transcribed as a 1.7-kb message
with “late” gene kinetics (Haggerty and Schleiss, 2002). No
homolog of this CK, by either sequence comparison or
colinear genomic positioning, was found to be present in the
genomes of other mammalian cytomegaloviruses by
BLAST search.
Expression and purification of GPCMV-MIP
Recombinant GPCMV-MIP was produced by expression
in mammalian cells. A His-tagged GPCMV-MIP expression
vector (pKTS 532) was transfected into HEK293 cells and
supernatants were collected and clarified 48 h posttransfec-
tion. Empty pcDNA4-transfected HEK293 supernatants
were collected in parallel as controls. Following incubation
of clarified supernatants with Ni2 agarose beads, beads
were formed into a column and washed and protein was
collected by elution. The purified GPCMV-MIP was ana-
lyzed by Coomassie staining of SDS–PAGE gels and con-
sisted predominantly of a single species with a relative
molecular mass (Mr) of 18 kDa (Fig. 2, left). The migra-
tion of the GPCMV-MIP at 18 kDa was slightly larger
than the Mr of 11 kDa predicted by the deduced amino
acid sequence (Haggerty and Schleiss, 2002), but was ac-
counted for by the additional 37 aa contributed by plasmid
polylinker sequence and the myc and poly-His tags, respec-
tively. Additionally, the predicted amino acid sequence for
GPCMV-MIP contains consensus motifs for PKC phos-
phorylation, myristylation, and N-linked glycosylation sites
and may be thus modified. Treatment of expressed protein
with the broad spectrum endoglycosylase PNGase F failed
to affect the observed mobility of the protein in SDS–
PAGE, indicating that the protein was not glycosylated in
our system. Minor bands were also present, but their mo-
lecular weights suggested that these may be multimers of
the base 18-kDa species, and their relative intensities sug-
gested these bands represented less than 5% of the recom-
binant preparation. Very little protein was recovered from
the control supernatant when processed under identical con-
ditions. Protein transferred to nylon was then stained with a
reagent detecting the His tag, which reacted with all species
in the GPCMV-MIP preparation, but not the control (Fig. 2,
right). Purified protein preparations were quantified by BCA
assay: approximate molar concentrations were determined,
and these preparations were used in the in vitro assays
below.
GPCMV-MIP stimulates intracellular calcium flux in
hCCR1-L1.2 transfectants
Because GPCMV-MIP has strongest homology to
hCCR1 ligands, we first tested the ability of GPCMV-MIP
to elicit intracellular calcium mobilization in L1.2 cells
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stably expressing hCCR1 (Fig. 3). GPCMV-MIP was found
to induce calcium flux in these cells in a dose-dependent
manner, and an EC50 was estimated by plotting the peak
response at each dose, giving an approximate EC50 of 52
nM (Fig 3). To further confirm that the GPCMV-MIP ac-
tivity is mediated through hCCR1, cross-desensitization
tests were performed. Sequential stimulation with hMIP -1
and GPCMV-MIP was used to assess the ability of each of
these chemokines to desensitize signaling to the other,
through hCCR1. When cells were treated first with 200 nM
GPCMV-MIP, the calcium response to 2 nM hMIP -1 was
completely inhibited. Conversely, 2 nM hMIP -1 could
completely inhibit the response to 200 nM of GPCMV-MIP
(Fig. 4). These data again suggested that hCCR1 is the
functional receptor for GPCMV-MIP. GPCMV-MIP may
be incompletely adapted to binding and activation of the
human receptor and may therefore exhibit a lower affinity
than the natural human ligand; however, the purification
procedure for expressed protein prohibited any further as-
sessment of absolute potency.
To ascertain whether the observed activity was hCCR1/
GPCMV-MIP-dependent, L1.2 hCCR1 cells were assayed
in the presence of a cell-equivalent amount of a control
Fig. 1. Genomic localization of GPCMV-MIP homolog. (A) Gene is localized to leftward region of viral genome, in leftward portion of HindIII “D” fragment.
(B) Deduced amino acid sequence of hMIP homolog is indicated. Potential cleavage site is marked, and cysteine residues are highlighted (upper part of
figure). GPCMV-MIP encodes a 101-aa polypeptide which phylogenetic analysis identifies as having identity to the hMIP subfamily of CC () chemokines
(bottom part of figure). Neighbor-join tree methodology (MacVector 7.0) with clustal alignment parameters: open gap penalty, 10; extend gap penalty, 0.1;
delay divergence, 40%; gap distance, 8; similarity matrix, BLOSUM.
Fig. 2. Purification of recombinant GPCMV-MIP. Protein was purified
from supernatants of GPCMV-MIP or control transfected HEK293 and
separated by SDS–PAGE. (A) Coomassie-stained gel showing purified
protein and multimers. (B) Immunoblot showing anti-His reactivity of the
purified GPCMV-MIP protein.
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eluent derived from empty vector transfected cells. No sig-
nal was observed in this case (Fig. 4). Additionally, we were
able to entirely inhibit the GPCMV-MIP response with a
small molecule antagonist specific to hCCR1 (CCX-A, with
an approximate IC50 of 5 M for hCCR1/hMIP-1 bind-
ing), indicating that the calcium flux observed following
stimulation with GPCMV-MIP was entirely mediated
through hCCR1 (Fig. 4). Neither GPCMV-MIP nor hMIP
-1 induced any signal in the untransfected parental L1.2
cells (data not shown). As hCCR1, hCCR2, and hCCR5 are
all known to be involved in cytokine-mediated proinflam-
matory responses, and both hCCR1 and hCCR5 share a
Fig. 3. Dose response of GPCMV-MIP-induced calcium flux on hCCR1-L1.2 cells. L1.2 cells stably transfected with human hCCR1 were loaded with
indo-1AM (Molecular Probes). GPCMV-MIP was added at various concentrations and the relative calcium signal (400/490 nM ratio) was recorded. Relative
response over basal levels was plotted for each concentration, and an EC50 was calculated by sigmoidal dose response regression analysis using Prism.
Fig. 4. Chemokine-induced calcium mobilization and cross-desensitization on hCCR1-L1.2 cells. (A and B) L1.2 cells stably transfected with human hCCR1
were loaded with indo-1AM (Molecular Probes). Chemokines were added at indicated concentrations and shown to elicit intracellular calcium mobilization
and cross desensitization. (C) A control eluate failed to stimulate calcium flux on the same cells. (D) Signaling to GPCMV-MIP, but not the ionomycin control
was inhibited by the addition of 10 M of the hCCR1 antagonist CCX-A. The y-axis represents relative increase in intracellular calcium release (400/490
nm ratio). Data shown are representative of at least three experiments.
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number of ligands, we assessed the ability of these receptors
to mediate a calcium response to GPCMV-MIP. HEK293
cells expressing either hCCR2 or hCCR5 were stimulated
with 200 nM GPCMV-MIP, followed by their natural hu-
man ligand. GPCMV-MIP was unable to elicit a response in
either of these cells, but both cell lines responded to their
cognate ligand (Fig. 5). In addition, GPCMV-MIP failed to
signal in cells transfected with CCR7, CCR9, CXCR4, or
the human cytomegalovirus chemokine receptor homolog,
US28 (data not shown), suggesting GPCMV-MIP was a
specific ligand for hCCR1. The signal magnitude obtained
with 200 nM GPCMV-MIP was comparable to that ob-
tained with 2 nM of hMIP-1. Similar results were obtained
in Jurkat cells which were stably transfected with hCCR1
(data not shown).
GPCMV-MIP induces migration of cells stably transfected
with hCCR1
To investigate whether the ability of GPCMV-MIP to
induce intracellular calcium release in hCCR1-L1.2 cells
has further functional consequences, we performed migra-
tion assays on hCCR1-L1.2 transfectants (Fig. 6). These
studies demonstrated that GPCMV-MIP was capable of
inducing migration. Migration was first observed at chemo-
kine concentrations of approximately 10 nM and was max-
imal at concentrations of approximately 100 nM. The bell-
shaped response curve showing diminishing activity at
higher concentrations of chemokine is due to saturation of
membrane receptors and is a characteristic of cell migration
Fig. 5. GPCMV-MIP is not active on hCCR2 and hCCR5. HEK293 cells
stably transfected with hCCR2 or hCCR5 were loaded with indo-1AM
(Molecular Probes). (A) The hCCR2 ligand MCP-1, or (B) the hCCR5
ligand RANTES, but not GPCMV-MIP, induced an increase in intracel-
lular calcium concentrations. The y-axis represents relative increase in
intracellular calcium release (400/490 nm ratio). Data shown are represen-
tative of at least three experiments.
Fig. 6. Chemotactic activity of GPCMV-MIP on hCCR1-L1.2 cells. Migration of hCCR1-L1.2 cells to a gradient of GPCMV-MIP was assessed in 96-well
ChemoTx microplates (Neuroprobe). Data indicate relative fluorescent signal in the lower well at completion of assay. Data shown are representative of at
least three experiments.
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to chemoattractants. The maximal response obtained with
GPCMV-MIP was comparable to migration induced with
hMIP -1, although the potency was significantly less. No
GPCMV-MIP-induced migration signal was observed in
response to equal volumes of control supernatant or in the
untransfected parental L1.2 cells, or L1.2 cells transfected
with other chemokine receptors (data not shown).
GPCMV-MIP competes 125I-MIP -1 binding on hCCR1-
L1.2 stable transfectants
To investigate whether GPCMV-MIP is able to compete
hMIP -1 binding to hCCR1-expressing cells, we compared
the ability of GPCMV-MIP and hMIP -1 to displace 125I-
labeled hMIP -1 binding on hCCR1-L1.2 cells (Fig. 7).
Competitive displacement of labeled hMIP -1 was ob-
served with increasing concentrations of GPCMV-MIP or
hMIP -1. Single-site competitive analysis showed that
hMIP -1 had an IC50 of approximately 0.6 nM, and
GPCMV-MIP had an IC50 of approximately 44 nM to
hCCR1, in agreement with the values obtained in the cal-
cium flux analysis and the migration assays.
GPCMV-MIP is synthesized in infected cells and is a
target of immune responses in GPCMV infection
To assay for synthesis of GPCMV-MIP in infected tissue
culture lysates, a GST-fusion protein was generated in E.
coli and used to immunize GPCMV-seronegative guinea
pigs. Antibody was used in RIP–PAGE assays following
labeling of GPCMV-infected GPL cells in tissue culture
with 35S. These studies (Fig. 6A) identified protein species
of10 and 12 kDa in the total cellular lysate, both of which
were immunoreactive with immune, but not preimmune,
serum generated against the GST fusion protein. To exam-
ine whether similar proteins were immunoprecipitated using
antisera generated in the context of viral infection, a poly-
clonal anti-GPCMV antisera was utilized and also found to
precipitate similarly sized protein species (data not shown).
To further examine whether polyclonal convalescent guinea
pig sera from GPCMV-infected animals was immunoreac-
tive with the GPCMV hMIP, ELISA assays were per-
formed, using the GST–MIP fusion protein. These experi-
ments indicated that polyclonal anti-GPCMV antisera (but
not nonimmune sera) was found to be immunoreactive with
the GST–MIP fusion protein, but not the GST carrier pro-
tein alone (Fig. 6B). We therefore conclude that GPCMV-
MIP is synthesized in the setting of viral infection in tissue
culture and appears to elicit an antibody response in the
setting of natural GPCMV infection in guinea pigs.
Discussion
In recent years it has become clear that all of the CMVs
encode homologs of host immunoregulatory genes, includ-
Fig. 7. Binding of GPCMV-MIP to hCCR1. hCCR1-L1.2 cells were incubated with 0.1 nM 125I-MIP -1 in the presence of increasing concentrations of
unlabeled (A) GPCMV-MIP, or (B) hMIP -1 for 3 h at 4°C. The IC50 for each interaction was determined by single site competitive analysis of the data
using Prism (GraphPad Software). Data shown are representative of at least two experiments.
Fig. 8. Immunological analyses of GPCMV-MIP (A) RIP–PAGE analysis of GPCMV-MIP. Uninfected tissue culture lysates (left side of panel, lanes 1, 2)
and GPCMV-infected tissue culture lysates (right side of panel, lanes 3, 4) were labeled with [35S]cysteiene/methionine and subjected to RIP–PAGE using
either a preimmune guinea pig sera (lanes 1, 3) or an antisera raised against a GST/GPCMV-MIP fusion protein expressed in E. coli (lanes 2, 4). Antibody
generated against GST-fusion protein, but not preimmune sera, immunoprecipitated putative GPCMV-MIP protein species of approximately10 and 12 kDa
(arrows). (B) ELISA analysis of GST–MIP fusion protein. Both nonimmune guinea pig serum and polyclonal GPCMV-immune sera obtained from
GPCMV-infected animals were evaluated for immunoreactivity by ELISA against both GST carrier protein (top) and GST-MIP fusion protein (bottom).
Vertical axis, OD units; horizontal axis, serum dilution factor. Data indicate mean SD of triplicate wells. Immune sera from GPCMV-infected animals (gray
bars), but not preimmune sera (white bars), was immunoreactive with GST-MIP (bottom), but not GST carrier protein (top), suggesting that GPCMV-MIP
elicits antibody responses in the context of viral infection.
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FIGURE 8
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ing CKs, GPCRs, and molecules which modulate antigen
processing and presentation, many apparently derived from
the host genome (Alcami and Koszinowski, 2000; Hengel et
al., 1998; Mocarski, 2002; Saederup and Mocarski, 2002;
Vink et al., 2001). The role of these “pirated” homologs in
viral pathogenesis remains uncertain, but presumably these
gene products contribute to evasion of host immune re-
sponses or to modulation of inflammatory responses which
may aid in dissemination of infection. Because of the strict
species-specificity of CMVs, the in vivo contribution of
these genes to HCMV disease can only be inferred from
analyses of related genes of other mammalian CMVs. To
facilitate the study of pathogenesis in vivo, we analyzed the
sequence of GPCMV for CK homologs, since the guinea pig
represents a uniquely useful small animal model for the
study of transplacental and fetal viral infection (Schleiss,
2002). The study of GPCMV is of particular relevance to
congenital HCMV infection, a common disease in the de-
veloped world which has profound impact on public health
(Stratton et al., 1999). Sequence analysis of GPCMV pre-
viously identified a CK homolog in the HindIII “D” region
of the viral genome which had identity with the CC or beta
CK family, encoded by an unspliced 1.7-kb RNA transcript
(Haggerty and Schleiss, 2002). In this study, we confirm
that this protein is synthesized in the setting of viral infec-
tion and authenticate the functionality of the protein as a
bona fide chemokine.
Analysis of the deduced coding sequence of the GPCMV
CK indicated that this ORF was capable of encoding a
101-aa protein with a predicted Mr of 11 kDa and a
predicted cleavage site at Val23. A BLAST search indicated
strong identity between this ORF and the CC () CK family.
Phylogenetically, the CC-CKs form three distinct clusters:
the macrophage inflammatory protein (MIP) subfamily, the
monocyte chemotactic protein (MCP) subfamily, and a third
subgroup containing human CK I-309 and two related
mouse CKs (Hughes and Yeager, 1999). BLAST compari-
son of the GPCMV CK suggested that it was a member of
the hMIP-1 subfamily, sharing the strongest identity
(BLAST score 170) with the CK, human chemotactic
cytokine-1 (HCC-1/CCL14), a secreted CK present in nano-
molar quantities in human plasma (Schulze-Knappe et al.,
1996). HCC-1 signals predominately through the CCR-1
receptor and appears to play a role in enhancing the prolif-
eration of monocyte progenitors, including CD34 cells
(Maciejewski and St. Jeor, 1999; Movassagh et al., 1996).
Functional assays of the recombinant GPCMV CK, desig-
nated GPCMV-MIP, corroborated the prediction of the mo-
lecular phylogenetic analysis. GPCMV-MIP purified from
transfected HEK293 supernatants was found to induce cal-
cium signaling and chemotaxis exclusively through the
hCCR1 receptor. Interestingly, the chemokine had no activ-
ity on the proinflammatory receptors hCCR2 and hCCR5,
which share at least some ligands with hCCR1. Signaling
was also not observed in cells expressing other CCRs,
including hCCR7, hCCR9, hCXCR4, and the human cyto-
megalovirus chemokine receptor homolog, US28. Activity
was of a similar order of magnitude, albeit with an appar-
ently slightly lower potency compared to hMIP -1
(CCL3), although our estimates of protein concentration
may be imperfect. It will be of interest in later studies to
assess the potency of this chemokine on its native receptor,
presumably guinea pig CCR1, should purified recombinant
material and appropriate cells lines become available. Com-
petitive desensitization of hMIP -1 by GPCMV-MIP and
vice versa was observed in the calcium flux analysis, sug-
gesting that the two chemokines may signal through a com-
mon G-protein. The ability of GPCMV-MIP to displace
radiolabeled hMIP -1 in our binding assays further sug-
gests that the two chemokines also share a common or
overlapping binding site on the hCCR1 receptor.
Previous analyses (Haggerty and Schleiss, 2002) indi-
cated that GPCMV-MIP transcription is strictly limited to
the late phase of replication, similarly to the MCMV CK,
MCK. To examine whether GPCMV-MIP could be iden-
tified from cells in tissue culture, infected fibroblasts
were pulse-labeled with [35S] methionine/cysteine, 96 h
postinfection, and total lysates were subjected to RIP–
PAGE, using a polyclonal antibody raised against a GST-
fusion protein made in E. coli. This antibody (but not the
respective preimmune sera) immunoprecipitated species
of 10 and 12 kDa from total tissue culture extracts of
infected, but not uninfected, guinea pig fibroblasts. Based
on the hydrophobicity profile of GPCMV-MIP and on
comparisons with other CKs, cleavage of a predicted
hydrophobic leader peptide at residue Val23 would yield
a mature polypeptide of 78 aa with a predicted Mr of 8.6
kDa. The higher Mr of the recombinant protein in
HEK293 cell supernatants suggests that the protein may
not be cleaved in these cells, or that host cell or viral
factors may influence posttranslational modification. The
primary predicted amino acid sequence of the GPCMV
MIP contains consensus motifs for PKC phosphorylation,
glycosylation, and myristilation. However, treatment of
the purified protein with PNGase F failed to alter its
mobility in SDS–PAGE, suggesting that the protein was
not subject to N-linked glycosylation in our system (data
not shown). Alternative splicing of the GPCMV-MIP
transcript could also explain variation in protein isoforms
identified by RIP–PAGE, although analysis of acceptor/
donor consensus sequences suggests an absence of splic-
ing in this region. Further studies will be required to
examine for splicing events, to define the extent of the
posttranslational modification(s) of GPCMV-MIP, and to
define which isoform(s) are functional. The finding of
immunoreactivity of immune sera from GPCMV-infected
animals with the GPCMV MIP–GST fusion protein (but
not the GST carrier) by ELISA was of interest, since this
observation suggests that GPCMV-MIP elicits an im-
mune response during GPCMV infection. Further studies
will be required to ascertain what, if any, role such
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antibody responses may have on functionality of the CK,
or on the pathogenesis of infection in vivo.
These observations add to the growing list of CMV
CKs that appear to have been transduced from the host
genome during the process of coevolution of host and
pathogen. HCMV encodes CXC chemokines UL146 and
UL147. UL146 has been shown to function as a potent
neutrophil chemoattractant through hCXCR2 (Penfold et
al., 1999; Saederup and Mocarski, 2002), while the ac-
tivity of UL147 has not been characterized, although the
protein is expressed in infected cells (M.E. Penfold, un-
published data). MCMV, in contrast, encodes a CC che-
mokine, MCK1, which may, via recruitment of mononu-
clear cells during acute infection, promote dissemination
of infection (Saederup et al., 1999, 2001). GPCMV-MIP
is unique among the CMV CKs described to date, con-
taining neither positional nor sequence homology with
HCMV or MCMV CKs. Based on phylogenetic compar-
isons, GPCMV-MIP is most similar among viral chemo-
kines to the vMIPs encoded by Kaposi’s sarcoma herpes-
virus (KSHV); however, in contrast to the KSHV vMIPs,
which signal in broad-spectrum fashion across a number
of CCRs (Moore et al., 1996; Nicholas et al., 1997), the
GPCMV-MIP appears to be likely to selectively mediate
signaling through a CCR1 receptor, but not other proin-
flammatory receptors. Although the function of this CK
could be to serve as a “decoy,” blocking the effect of the
native guinea pig MIP protein and thereby limiting the
immune response to infection, its biological activity in
our assays suggest it is more likely that GPCMV-MIP
serves as a proinflammatory mediator which could func-
tion to facilitate dissemination of virus in vivo. Recruit-
ment of leukocytes to sites of viral infection, mediated
via a viral CK, could thereby provide additional vehicles
for viral dissemination, aiding in further potentiation of
viral infection, or establishment of latency. Examination
of the in vivo phenotype of a GPCMV-MIP deletion virus
(Haggerty and Schleiss, 2003) will provide a clearer
explanation of the role of this CK in viral pathogenesis.
It is of particular interest to consider the potential roles of
viral CKs in the development of placental infection and
inflammation in the guinea pig model of congenital CMV
infection. Successful pregnancy requires down-regula-
tion of proinflammatory Th-1 cytokines (Raghupathy,
2001). In the context of GPCMV infection in pregnant
dams, viral CKs could, by promoting inflammatory re-
sponses in the infected placenta, compromise fetal sur-
vival and development. The discovery of an active che-
mokine homolog in GPCMV offers a unique opportunity
to examine the role of these molecules in the in vivo
setting of congenital infection. In addition to providing
insights into the pathogenesis of infection, elucidation of
the role a viral CK plays in this small animal model of
transplacental CMV infection could have implications for
CMV vaccine design and development of novel thera-
peutic strategies.
Materials and methods
Cells and virus
GPCMV (strain 21222, ATCC VR682) was propagated
on guinea pig fibroblast lung cells (GPL, ATCC CCL 158)
and maintained in F-12 medium supplemented with 10%
fetal calf serum (FCS, HyClone, UT), 10,000 IU/I penicil-
lin, 10 mg/l streptomycin (Gibco-BRL), and 7.5% NaHCO3
(Gibco-BRL, CA). Human embryonic kidney (HEK) 293
cells (ATCC CRL1573) were utilized for protein expression
and were grown in DMEM (Hyclone) supplemented with
5% FCS. Murine L1.2 cells (ATCC HB204) stably trans-
fected with human CCR1 were prepared by using Superfect
reagent (Qiagen, CA) following the manufacturer’s speci-
fications. HEK 293 cells (ATCC CRL1573) stably trans-
fected with human CCR2 or CCR5 were prepared by using
Superfect reagent (Qiagen) following the manufacturer’s
specifications. Cells were maintained in RPMI with 10%
FCS with 2 mg/ml G-418 (ICN, CA), and treated with 8 mM
sodium butyrate (Sigma, MO) 16 h prior to the experiment.
Plasmid constructs
The details regarding the cloning of the GPCMV-MIP
gene, and details regarding relevant plasmid constructs, are
described elsewhere (Haggerty and Schleiss, 2002). For
protein expression studies, a PCR-based site-directed mu-
tagenesis strategy was employed to modify the native
GPCMV-MIP stop codon (from a TAG codon to an AAG
codon), utilizing the following oligonucleotide primers:
5-AGGCCTTGGGGGAACGAGCGGAATGAGAAAG-3
and 5-GGCGCACGAATCGTATCTTGGCCTGCTGCA-
3. Following PCR amplification and subcloning into the
vector pCR2.1 (Invitrogen), the modified GPCMV-MIP was
next excised as an EcoRI fragment and subcloned into the
EcoRI site of pcDNA 4.0 myc-His version C (Invitrogen,
CA), yielding plasmid pKTS 532. This vector tagged the
carboxy-terminus of the protein with a 6-His tag for affinity
purification. This same EcoRI fragment was cloned into the
EcoRI site of the GST expression vector, pGEX-2T (Phar-
macia, NJ), for generation of fusion protein in E. coli,
according to the manufacturer’s specifications.
Generation of GPCMV-MIP antisera
Inbred adult strain-2 guinea pigs were purchased from
the Children’s Hospital Research Foundation (Cincinnati,
OH). All animal experiments were performed in accordance
with guidelines approved by the American Association of
Accreditation of Laboratory Animal Care and were ap-
proved by the Animal Use Care Committee of Children’s
Hospital Research Foundation. The GPCMV-MIP CK pro-
tein expressed as a GST fusion protein was purified using
glutathione agarose, and immunogen (50 g) was adminis-
tered subcutaneously, with Freund’s adjuvant. Animals
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were bled and antibody responses were quantified by
ELISA assay as described elsewhere (Schleiss, 2002), using
100 ng of purified GST-MIP, or the parental GST protein as
a control. ELISA assays against purified GST and GST-MIP
were also performed with nonimmune guinea pig antisera,
and convalescent, polyclonal anti-GPCMV antibody from
GPCMV-infected animals.
Characterization of GPCMV-MIP protein expression
For protein expression, HEK293 cells were transiently
transfected using Superfect according to the manufacturer’s
instructions (Qiagen) with plasmid pKTS 532. Supernatants
were collected 48 h posttransfection, clarified by low-speed
centrifugation, and incubated overnight at 4°C with agarose
resin-bound Ni2 (Ni-NTA, Qiagen) in the presence of 10
mM imidazole. Resin was formed into a column, washed
with 25 mM imidazole in purification buffer (50 mM
NaH2PO4, 300 mM NaCl, pH 8.0), and eluted with 500 mM
imidazole in purification buffer. Supernatant from nontrans-
fected HEK 293 cells was processed in parallel. Eluent
protein was separated by SDS–PAGE and stained with
Coomassie blue (Pierce, IL) or transferred to nylon mem-
branes for subsequent Western blot analyses. Blots were
washed in Tris-buffered saline (TBS), blocked with TBS/
0.05% Tween/0.5% bovine serum albumin (BSA), and then
incubated with INDIA-Hisprobe-HRP detection reagent
(Pierce). Blots were then washed three times in TBS/0.5%
Tween, and protein was detected using West-Pico HRP
detection reagent (Pierce) according to the manufacturer’s
specifications, followed by exposure to Kodak XOMAT film.
Protein in eluate fractions was quantified by the BCA method
according to the manufacturer’s instructions (Pierce).
For identification of GPCMV-MIP in infected tissue cul-
ture, GPL cells were inoculated with GPCMV (multiplicity
of infection 5 PFU/cell) and at 96 h postinfection, cells
were incubated with media supplemented with [35S]-cys-
teine and methionine (35S-Translabel, ICN Radiochemicals,
CA) at a specific activity of 50 Ci/ml, for 4 h. Proteins
from total cellular lysates were precleared with nonimmune
guinea pig sera Staphylococcus aureus protein A to remove
nonspecific immunoreactivity, then immunoprecipitated
with antibody generated against the GPCMV-MIP GST
fusion protein, and S. aureus protein A, and subjected to
SDS–PAGE and autoradiography as previously described
(Schleiss et al., 1999).
Calcium signaling analyses
Calcium mobilization assays were performed using an
intracellular ratiometric fluorescent dye, Indo-1AM (Molec-
ular Probes, OR). The hCCR1 L1.2 cells or wild-type L1.2
cells were loaded with Indo-1/AM (3 M) in culture me-
dium (45 min, 20°C, 107 cells/ml). After dye loading, cells
were washed once with PBS and resuspended at 106
cells/ml in Hank’s balanced salt solution (HBSS, Gibco)
containing 1% FCS. Cytosolic calcium release was deter-
mined using excitation at 350 nm using a Photon Technol-
ogy International fluorimeter (excitation at 350 nm, ratioed
dual emission at 400 and 490 nm). Cross-desensitization
tests were performed while cells were stimulated sequen-
tially with chemokines as indicated.
Cell migration assays
For these studies, hCCR1-L1.2 cells were harvested with
trypsin, centrifuged, and resuspended in chemotaxis me-
dium (CM; HBSS/1 mM CaCl2/1 mM MgSO4/0.1% BSA).
Assays were performed in 96-well ChemoTx microplates
with a 5-m pore size (Neuroprobe, MD). Chemokines
were added to the lower wells (final volume 29 L), and 20
L of cell suspension (5  106 cells/mL) was added to the
polycarbonate filters. After incubation for 90 min (37°C,
100% humidity, 5% CO2), the upper chamber was removed
and cells that migrated into the lower chamber were quan-
tified with the CyQuant assay kit (Molecular Probes).
Ligand binding analyses
For binding studies, hCCR1-L1.2 cells were incubated
with 125I-labeled hMIP -1 (final concentration 0.05 nM;
New England Nuclear, MA) in the presence of serial dilu-
tions of unlabeled chemokine competitor (3 h at 4°C: 25
mM HEPES, 140 mM NaCl, 1 mM CaCl2, 5 mM MgCl2,
and 0.2% BSA, pH 7.1). Reactions were aspirated onto
PEI-treated GF/B glass filters using a cell harvester (Pack-
ard, CA). Filters were washed twice (25 mM HEPES, 500
mM NaCl, 1 mM CaCl2, 5 mM MgCl2, pH 7.1). Scintillant
was added and filters and counted in a Packard Topcount
scintillation counter. Data were subjected to single site
competitive analysis and plotted using Prism (GraphPad
Software, CA).
Note added in proof
Since the submission of this manuscript, a putative beta
chemokine gene has been described in the human cyto-
megalovirus genome (Akter, P., Cunningham, C., Mc-
Sharry, B.P., Dolan, A., Addison, C., Dargan, D.J., Hassan-
Walker, A.F., Emery, V.C., Griffiths, P.D., Wilkinson,
G.W., Davison, A.J., 2003. J. Gen. Virol. 84, 1117–1122).
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